化工社化工社 化学情報印刷レポート · 研究参考用
ソタグリフロジン
(2S,3R,4R,5S,6R)-2-(4-クロロ-3-(4-エトキシベンジル)フェニル)-6-(メチルチオ)テトラヒドロ-2H-ピラン-3,4,5-トリオール · ソタグリフロジン · (2S,3R,4R,5S,6R)-2-{4-クロロ-3-[(4-エトキシフェニル)メチル]フェニル}-6-(メチルスルファニル)オキサン-3,4,5-トリオール · Sotagliflozin · LX4211/Sotagliflozin-API · β-L-Xylopyranoside,methyl5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-,(5S)- · (5S)-Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-beta-L-xylopyranoside Sotagliflozin LP 802034 · LX421
識別子と物理属性
| CAS No. | 1018899-04-1 |
|---|---|
| 分子式 | C21H25ClO5S |
| 平均分子量 | 424.9 g/mol |
| 単同位体質量 | 424.1111228 g/mol |
| SMILES | CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1 |
| InChIKey | QKDRXGFQVGOQKS-CRSSMBPESA-N |
| PubChem CID | 24831714 |
| ChEMBL | CHEMBL3039507 |
| ChEBI | CHEBI:229226 |
| EC No. | 805-113-6 |
| DTXSID | DTXSID20144314 |
| 現地名 | ソタグリフロジン |
化学・物理的性質
| XLogP | 3.2 |
|---|---|
| 極性表面積 | 104 |
| 水素結合供与体数 | 3 |
| 水素結合受容体数 | 6 |
| 回転可能結合数 | 6 |
| 重原子数 | 28 |
| 形式電荷 | 0 |
| 複雑度 | 476 |
| 医薬品 | Pharmaceuticals -> Listed in ZINC15 |
| Human Drugs | Breast FeedingLactationMilk, HumanHypoglycemic AgentsSodium-Glucose Cotransporter 2 InhibitorsSGLT2 InhibitorsFDA approved drugs -> Active ingredient |
| 沸点 | 607.9±55.0 °C(Predicted) |
| 密度 | 1.37±0.1 g/cm3(Predicted) |
| 貯蔵条件 | Store at -20°C |
| 溶解度 | DMSO:84.0(Max Conc. mg/mL)197.67(Max Conc. mM)Ethanol:17.0(Max Conc. mg/mL)40.01(Max Conc. mM) |
| pKa（酸解離定数） | 12.87±0.70(Predicted) |
| 外観・状態 | Powder |
| 色 | White to off-white |
| InChIKey | QKDRXGFQVGOQKS-WFCPIQDQNA-N |
| SMILES | [C@@H]1(C2=CC=C(Cl)C(CC3=CC=C(OCC)C=C3)=C2)O[C@H](SC)[C@@H](O)[C@H](O)[C@H]1O |&1:0,19,22,24,26,r| |
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 50% (2 of 4) of reports.WarningH302 (25%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 4 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (25%) |
| Hepatotoxicity | In two large pre-registration, placebo-controlled cardiovascular outcome trials that enrolled more than 11,000 patients, serum aminotransferase elevations were no more frequent with sotagliflozin than with placebo. Rates of ALT elevations above 3 times the upper limit of normal (ULN) were similar between treatment groups (2.0% vs 2.1% in the heart failure trial0.9% vs 0.9% in the diabetes and kidney disease trial), and mean aminotransferase levels did not change with treatment. Potential cases of drug-induced liver injury, adjudicated by a committee blinded to the treatment group, occurred at similarly low rates in the sotagliflozin and placebo patients [1.8% vs 2.3% and 0.7% vs 0.6%]. A single sotagliflozin-treated patient met laboratory criteria for clinically apparent liver injury with jaundice, but the event occurred months after stopping the drug and was judged to be due to biliary obstruction from gallstones. The product label does not list liver injury as an adverse reaction. Since its approval, there have been no published reports of clinically apparent liver injury attributed to sotagliflozin, but clinical experience with the drug has been limited. As with other agents in the SGLT2 inhibitor class, sotagliflozin appears to be an unlikely cause of liver injury. |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 危険有害性情報 | コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H351 |
用途
使用
Sotagliflozin is used for the treatment of patients with type 1 diabetes mellitus.